174 related articles for article (PubMed ID: 37925144)
21. Overuse of Oral Corticosteroids, Underuse of Inhaled Corticosteroids, and Implications for Biologic Therapy in Asthma.
Eger K; Amelink M; Hashimoto S; Hekking PP; Longo C; Bel EH
Respiration; 2022; 101(2):116-121. PubMed ID: 34535586
[TBL] [Abstract][Full Text] [Related]
22. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
23. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.
Pavord I; Gardiner F; Heaney LG; Domingo C; Price RG; Pullan A; Oppenheimer J; Brusselle G; Nagase H; Chupp G; Pizzichini E; Bañas-Conejero D; Howarth P
Front Immunol; 2023; 14():1150162. PubMed ID: 37122713
[TBL] [Abstract][Full Text] [Related]
24. Factors to Consider in Prescribing Asthma Biologic Therapies to Children.
Anderson WC; Banzon TM; Chawes B; Papadopoulos NG; Phipatanakul W; Szefler SJ
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):693-701. PubMed ID: 36646381
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy.
Breslavsky A; Al Qaied A; Tsenter P; Mukaseev N; Alamor M; Cohen-Hagai K; Wand O
Respir Med; 2024 Feb; 222():107528. PubMed ID: 38199287
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
27. Barriers to clinical remission in severe asthma.
Farinha I; Heaney LG
Respir Res; 2024 Apr; 25(1):178. PubMed ID: 38658975
[TBL] [Abstract][Full Text] [Related]
28. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV
Pérez de Llano L; Dávila I; Martínez-Moragón E; Domínguez-Ortega J; Almonacid C; Colás C; García-Rivero JL; Carmona L; García de Yébenes MJ; Cosío BG;
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2725-2731. PubMed ID: 33549843
[TBL] [Abstract][Full Text] [Related]
29. Super-Responders to Biologic Treatment in Type 2-High Severe Asthma: Passing Fad or a Meaningful Phenotype?
Portacci A; Dragonieri S; Carpagnano GE
J Allergy Clin Immunol Pract; 2023 May; 11(5):1417-1420. PubMed ID: 36720387
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
31. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
[TBL] [Abstract][Full Text] [Related]
32. Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults.
Perez-de-Llano L; Scelo G; Tran TN; Le TT; Fagerås M; Cosio BG; Peters M; Pfeffer PE; Al-Ahmad M; Al-Lehebi RO; Altraja A; Bergeron C; Bjermer LH; Bjerrum AS; Bulathsinhala L; Busby J; Cano Rosales DJ; Canonica GW; Carter VA; Charriot J; Christoff GC; Denton EJ; Dorscheid DR; Fernandez Sanchez MJ; Fonseca JA; Gibson PG; Goh CYY; Heaney LG; Heffler E; Hew M; Iwanaga T; Katial R; Koh MS; Kuna P; Larenas-Linnemann DES; Lehtimäki L; Mahboub B; Martin N; Matsumoto H; Menzies-Gow AN; Papadopoulos NG; Popov TA; Porsbjerg CM; Patel P; Rhee CK; Sadatsafavi M; Taillé C; Torres-Duque CA; Tsai MJ; Ulrik CS; Upham JW; von Bülow A; Wang E; Wechsler ME; Price DB
Am J Respir Crit Care Med; 2024 May; ():. PubMed ID: 38701495
[TBL] [Abstract][Full Text] [Related]
33. Super-responder and clinical remission in patients with asthma on treatment with single biologic therapy or cycling therapy using dupilumab in a real-world setting.
Hamada S; Ogino E; Yasuba H
Int J Clin Pharmacol Ther; 2024 Feb; 62(2):61-68. PubMed ID: 38085095
[TBL] [Abstract][Full Text] [Related]
34. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
35. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
[TBL] [Abstract][Full Text] [Related]
36. Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.
Carpagnano GE; Portacci A; Nolasco S; Detoraki A; Vatrella A; Calabrese C; Pelaia C; Montagnolo F; Scioscia G; Valenti G; D'Amato M; Caiaffa MF; Triggiani M; Scichilone N; Crimi C
Front Immunol; 2024; 15():1343362. PubMed ID: 38327518
[TBL] [Abstract][Full Text] [Related]
37. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
38. Effect of inhaled corticosteroid use on weight (BMI) in pediatric patients with moderate-severe asthma.
Han J; Nguyen J; Kim Y; Geng B; Romanowski G; Alejandro L; Proudfoot J; Xu R; Leibel S
J Asthma; 2019 Mar; 56(3):263-269. PubMed ID: 29672188
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Real-World Escalation to Biologics in US Patients With Asthma.
Bender B; Oppenheimer J; George M; Brown R; Patel A; Hill T; Boe A; Mayen Herrera E; Dotiwala Z; Casciano J; Bernstein JA
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2941-2948. PubMed ID: 35931363
[TBL] [Abstract][Full Text] [Related]
40. The Relationship of Asthma Biologics to Remission for Asthma.
Menzies-Gow A; Szefler SJ; Busse WW
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1090-1098. PubMed ID: 33130146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
